{"id":170,"date":"2020-08-31T00:07:35","date_gmt":"2020-08-30T19:07:35","guid":{"rendered":"http:\/\/curesteps.org\/SCI\/?p=170"},"modified":"2021-01-06T19:04:13","modified_gmt":"2021-01-06T14:04:13","slug":"stem-cells","status":"publish","type":"post","link":"http:\/\/curesteps.org\/SCI\/stem-cells\/","title":{"rendered":"Alliance for Regenerative Medicine (ARM) Neuralstem Presentation"},"content":{"rendered":"\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" title=\"Neuralstem\" width=\"580\" height=\"326\" src=\"https:\/\/www.youtube.com\/embed\/fBQHDE0vnmA?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n\n\n\n<p>Alliance for Regenerative Medicine (ARM) Neuralstem Presentation<br>April 17, 2018<br>Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. The company\u2019s lead asset and stem cell therapy candidate,\u00a0<strong>NSI-566<\/strong>, is a spinal cord-derived neural stem cell line being tested in Amyotrophic Lateral Sclerosis (ALS),\u00a0<strong>chronic spinal cord injury (cSCI)<\/strong>\u00a0and ischemic stroke. Additionally, NSI-189, is a chemical entity in development for major depressive disorder (MDD) and for Angelman syndrome, irradiation-induced cognitive impairment, neuropathy associated with Type 1 and Type 2 diabetes and stroke. These product candidates are based on the company\u2019s proprietary neural stem cell technology.\u00a0<a href=\"http:\/\/www.neuralstem.com\/\">http:\/\/www.neuralstem.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alliance for Regenerative Medicine (ARM) Neuralstem PresentationApril 17, 2018Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. The company\u2019s lead asset and stem cell therapy candidate,\u00a0NSI-566, is a spinal cord-derived neural stem cell line being tested in Amyotrophic Lateral Sclerosis (ALS),\u00a0chronic spinal cord injury (cSCI)\u00a0and ischemic [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[10,12,11,8],"class_list":["post-170","post","type-post","status-publish","format-standard","hentry","category-stem-cells","tag-neuralstem","tag-nsi-566","tag-regenerative-medicine","tag-stem-cells"],"_links":{"self":[{"href":"http:\/\/curesteps.org\/SCI\/wp-json\/wp\/v2\/posts\/170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/curesteps.org\/SCI\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/curesteps.org\/SCI\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/curesteps.org\/SCI\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/curesteps.org\/SCI\/wp-json\/wp\/v2\/comments?post=170"}],"version-history":[{"count":3,"href":"http:\/\/curesteps.org\/SCI\/wp-json\/wp\/v2\/posts\/170\/revisions"}],"predecessor-version":[{"id":263,"href":"http:\/\/curesteps.org\/SCI\/wp-json\/wp\/v2\/posts\/170\/revisions\/263"}],"wp:attachment":[{"href":"http:\/\/curesteps.org\/SCI\/wp-json\/wp\/v2\/media?parent=170"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/curesteps.org\/SCI\/wp-json\/wp\/v2\/categories?post=170"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/curesteps.org\/SCI\/wp-json\/wp\/v2\/tags?post=170"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}